AN ACT Relating to establishing safety and regulatory requirements for compounded medications;
HB2613 establishes new state requirements for the sale, transfer, and distribution of compounded medications in Washington, with a particular focus on compounded drugs that use bulk active pharmaceutical ingredients. The bill is built around legislative findings that contaminated, substandard, or improperly sourced ingredients can enter the supply chain and jeopardize patient safety, especially in connection with weight-loss medications and other high-demand compounded products.
The bill makes it unlawful to compound drugs using bulk drug substances unless the substances meet specified federal and pharmacopeial standards, are tied to approved or otherwise authorized FDA pathways, and are accompanied by documentation such as certificates of analysis and proof of manufacturing conditions. It also requires quality-control testing, record retention, and inspection access for the pharmacy commission or its agents. Violations can trigger penalties including a per-dose fine and revocation of the pharmacy license. The act also includes a severability-style federal conformity clause and declares an emergency, making it effective immediately.
HB2613 would add a new regulatory framework to chapter 18.64 RCW governing pharmacy compounding and the sourcing of active pharmaceutical ingredients. It expands state oversight over pharmacies, wholesalers, repackagers, and other suppliers involved in compounded drugs by imposing sourcing, testing, documentation, inspection, and recordkeeping obligations, and by authorizing enforcement through fines and license revocation. The bill is intended to operate consistently with federal Food, Drug, and Cosmetic Act requirements and to yield to federal law where necessary to preserve federal funding or avoid conflict.
The bill text reflects a strongly protective, public-safety-oriented posture, emphasizing patient harm, contaminated ingredients, and gaps in federal enforcement. No committee transcript or vote record is provided, so there is no documented legislative debate or recorded vote sentiment to assess. Based on the bill’s findings and emergency clause, the measure appears to be framed as urgent and precautionary rather than controversial in its stated purpose.
The main policy tension in HB2613 is between tighter state controls on compounded medications and the practical burdens those controls may place on pharmacies and suppliers that rely on bulk drug substances. The bill’s strict sourcing, testing, inspection, and documentation requirements could be viewed as necessary consumer protection by supporters, while opponents might argue they increase compliance costs, restrict access to compounded medications, or duplicate federal oversight. The bill also specifically references foreign entities and weight-loss drug supply issues, suggesting concern over imported ingredients and high-demand products as a focal point of the regulation.